# Symvess (symvess) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/symvess

> The FDA approved Symvess (symvess), sponsored by Humacyte, Inc. (HUMA), on December 19, 2024 for extremity Vascular Trauma.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Symvess (symvess) |
| Codes |  |
| Sponsor | Humacyte, Inc. (HUMA) https://sec-api.dev/companies/huma/catalysts |
| Indications | extremity vascular trauma |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### August 10, 2024: PDUFA date

- Status: scheduled. Date confidence: exact.
- First seen 2025-03-27, last confirmed 2025-11-12.
- Press release filed with the SEC (EX-99) (accession 0001104659-25-028830): "Although our original PDUFA date was August 10, 2024, the FDA took an additional 19 weeks to complete its review of the risks and benefits of Symvess." https://www.sec.gov/Archives/edgar/data/1818382/000110465925028830/tm2510708d1_ex99-1.htm
- SEC Form 10-K (accession 0001818382-25-000034): "In February 2024, the FDA accepted the BLA filing and granted Priority Review, setting a PDUFA date of August 10, 2024." https://www.sec.gov/Archives/edgar/data/1818382/000181838225000034/huma-20241231.htm
- SEC Form 10-K (accession 0001818382-25-000034): "In February 2024, the FDA accepted the BLA filing and granted priority review and set a PDUFA date of August 10, 2024." https://www.sec.gov/Archives/edgar/data/1818382/000181838225000034/huma-20241231.htm
- SEC Form 10-Q (accession 0001818382-25-000132): "In February 2024, the FDA accepted the BLA filing, granted priority review and set a Prescription Drug User Fee Act date of August 10, 2024." https://www.sec.gov/Archives/edgar/data/1818382/000181838225000132/huma-20250930.htm
- SEC Form 10-Q (accession 0001818382-25-000125): "In February 2024, the FDA accepted the BLA filing, granted priority review and set a Prescription Drug User Fee Act date of August 10, 2024." https://www.sec.gov/Archives/edgar/data/1818382/000181838225000125/huma-20250630.htm
- SEC Form 10-Q (accession 0001818382-25-000076): "In February 2024, the FDA accepted the BLA filing and granted priority review and set a Prescription Drug User Fee Act date of August 10, 2024." https://www.sec.gov/Archives/edgar/data/1818382/000181838225000076/huma-20250331.htm
- SEC Form 10-K (accession 0001818382-25-000034): "Act ("PDUFA") date, the FDA action date for its regulatory decision regarding the BLA, of August 10, 2024." https://www.sec.gov/Archives/edgar/data/1818382/000181838225000034/huma-20241231.htm

### December 19, 2024: FDA approval

- Status: completed, approved. Date confidence: exact. Indication: Extremity Vascular Trauma.
- First seen 2024-12-20, last confirmed 2026-03-19.
- Press release filed with the SEC (EX-99) (accession 0001818382-24-000227): "Humacyte Announces FDA Approval of SYMVESS™ (acellular tissue engineered vessel-tyod) for the Treatment of Extremity Vascular Trauma" https://www.sec.gov/Archives/edgar/data/1818382/000181838224000227/huma-20241219xexx991.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-031780): "FDA approved Symvess® (ATEV) BLA in December 2024 for treatment of extremity vascular trauma; U.S. market launch commenced 2025" https://www.sec.gov/Archives/edgar/data/1818382/000110465926031780/tm269106d1_ex99-1.htm

### November 10, 2026: earnings report

- Status: completed. Date confidence: exact.
- First seen 2026-11-10, last confirmed 2026-11-10.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-454402): "Humacyte Reports Third Quarter 2026 Results, Highlighted by More Than Doubling Symvess Revenue and Expanding Commercial Adoption" https://www.sec.gov/Archives/edgar/data/1818382/000119312526454402/huma-ex99_1.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/symvess.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Symvess (symvess) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/symvess

```bibtex
@misc{secapidev_pdufa_symvess_20261116,
  title        = {Symvess (symvess) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/symvess}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_symvess_20261116","title":"Symvess (symvess) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/symvess","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
